New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: Diversity in the excitation-contraction mechanisms of the heart

Journal of Pharmacological Sciences

Volumn 109, Issue 3, 2009, Pages 327-333

  Tanaka, Hikaru ^a   Namekata, Iyuki ^a   Nouchi, Hideaki ^a   Shigenobu, Koki ^a   Kawanishi, Tom ^b   Takahara, Akira ^a  

^a TOHO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Action potential; Autonomic nervous system; Calcium ion; Cardiac disease; Contraction; Heart

Indexed keywords

CALCIUM ION; CHLORIDE CHANNEL BLOCKING AGENT; CHROMANOL 293B; CYCLOPIAZONIC ACID; EFONIDIPINE; MUSCARINIC RECEPTOR; NICARDIPINE; PHOSPHOLIPASE C; RYANODINE; SODIUM CHANNEL BLOCKING AGENT; TERFENADINE;

ATRIOVENTRICULAR BLOCK; DRUG ACTIVITY; HEART ATRIUM FIBRILLATION; HEART CONTRACTION; HEART DEPOLARIZATION; HEART EXCITATION; HEART FAILURE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE POTENTIAL; HEART RATE; HEART REPOLARIZATION; NONHUMAN; PACEMAKER; SHORT SURVEY; SINUS NODE;

ACTION POTENTIALS; ADENOSINE TRIPHOSPHATE; ANIMALS; CALCIUM; DISEASE MODELS, ANIMAL; HEART DISEASES; HUMANS; ION CHANNELS; MITOCHONDRIA, HEART; MYOCARDIAL CONTRACTION; SPECIES SPECIFICITY;

EID: 67249136466     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08R22FM     Document Type: Short Survey

References (39)

1. Boyett MR, Honjo H, Kodama I. The sinoatrial node, a heterogeneous pacemaker structure. Cardiovasc Res. 2000;47:658-687.
2. Ono K, Iijima T. Ionic and molecular basis of cardiac auto- maticity in mammalian heart. In: Mizukami Y, Ohtsuka T, editors. Molecular mechanisms of heart diseases. Trivandrum: Research SignPost; 2005. p.1-22.
3. Tanaka H, Komikado C, Namekata I, Nakamura H, Suzuki M, Tsuneoka Y, et al. Species difference in the contribution of T- type calcium current to cardiac pacemaking as revealed by efonidipine. J Pharmacol Sci. 2008;107:99-102.
4. Maltsev VA, Vinogradova TM, Lakatta EG. The emergence of a general theory of the initiation and strength of the heartbeat. J Pharmacol Sci. 2006;100:338-369.
5. Honjo H, Inada S, Lancaster MK, Yamamoto M, Niwa R, Jones SA, et al. Sarcoplasmic reticulum Ca2+ release is not a dominating factor in sinoatrial node pacemaker activity. Circ Res. 2003;92:e41-e44.
6. Lancaster MK, Jones SA, Harrison SM, Boyett MR. Intracellular Ca2+ and pacemaking within the rabbit sinoatrial node: heterogeneity of role and control. J Physiol. 2004;556(Pt 2):481-494.
7. Melnyk P, Ehrlich JR, Pourrier M, Villeneuve L, Cha TJ, Nattel S. Comparison of ion channel distribution and expression in cardiomyocytes of canine pulmonary veins versus left atrium. Cardiovasc Res. 2005;65:104-116.
8. Tanaka H, Shigenobu K. Species difference in myocardial excitation-contraction coupling featuring the mouse. Curr Topics Pharmacol. 2003;7:247-256.
9. Tanaka H, Sekine T, Nishimaru K, Shigenobu K. Role of sarcoplasmic reticulum in myocardial contraction of neonatal and adult mice. Comp Biochem Physiol A Mol Integr Physiol. 1998;120:431-438.
10. Kurokawa J, Suzuki T, Furukawa T. New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: Acute effects of female hormones on cardiac ion channels and cardiac repolarization. J Pharmacol Sci. 2009;109:334-340.
11. Sugiyama A, Ishida Y, Satoh Y, Aoki S, Hori M, Akie Y, et al. Electrophysiological, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT-prolonging drugs. Jpn J Pharmacol. 2002;88:341-350.
12. Takahara A, Nakamura H, Nouchi H, Tamura T, Tanaka T, Shimada H, et al. Analysis of arrhythmogenic profile in a canine model of chronic atrioventricular block by comparing in vitro effects of the class III antiarrhythmic drug nifekalant on the ventricular action potential indices between normal heart and atrioventricular block heart. J Pharmacol Sci. 2007;103:181-188. (Pubitemid 46294650)
13. Kato Y, Masumiya H, Agata N, Tanaka H, Shigenobu K. Developmental changes in action potential and membrane currents in fetal, neonatal and adult guinea-pig ventricular myocytes. J Mol Cell Cardiol. 1996;28:1515-1522. (Pubitemid 26340905)
14. Agata N, Tanaka H, Shigenobu K. Developmental changes in action potential properties of the guinea pig myocardium. Acta Physiol Scand. 1994;149:331.
15. Nouchi H, Kiryu N, Tanaka H, Shigenobu K. Developmental changes in the effect of K channel blockers on the chick ventricular action potential. J Pharmacol Sci. 2007;103:SuppI I:202P.
16. Tanaka H, Sekine T, Kawanishi T, Nakamura R, Shigenobu K. Intrasarcomere [Ca2+] gradients and their spatio-temporal relation to Ca2+ sparks in rat cardiomyocytes. J Physiol. 1998;508:145-152.
17. Seki S, Nagashima M, Yamada Y, Tsutsuura M, Kobayashi T, Namiki A, et al. Fetal and postnatal development of Ca2+ transients and Ca2+ sparks in rat cardiomyocytes. Cardiovasc Res. 2003;58:535-548. (Pubitemid 36694439)
18. Tanaka H, Masumiya H, Sekine T, Kawanishi T, Hayakawa T, Miyata S, et al. Involvement of Ca2+ waves in excitation contraction coupling of rat atrial cardiomyocytes. Life Sci. 2001;70:715-726. (Pubitemid 34056567)
19. Endoh M. Signal transduction and Ca2+ signaling in intact myocardium. J Pharmacol Sci. 2006;100:525-537.
20. Ishii K, Shigenobu K. Kasuya Y. Postjunctional supersensitivity in young rat heart produced by immunological and chemical sympathectomy. J Pharmacol Exp Ther. 1982;220:209-215.
21. Ishii K, Ishii N, Shigenobu K, Kasuya Y. Acetylcholine super- sensitivity in the rat heart produced by neonatal sympathectomy. Can J Physiol Pharmacol. 1985;63:898-899.
22. Tanaka H, Shigenobu K. Role of //-adrenoceptor-adenylate cyclase system in the developmental decrease in sensitivity to isoproterenol in fetal and neonatal rat heart. Br J Pharmacol. 1990;100:138-142.
23. Tanaka H, Kasuya Y, Shigenobu K. Altered responsiveness to autonomic transmitters of hearts from neonatal spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1988;12:678-682.
24. Ieda M, Fukuda K. New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: The regulatory mechanisms of cardiac innervation and their critical roles in cardiac performance. J Pharmacol Sci. 2009;109:348-353.
25. Okumura S, Suzuki S, Ishikawa Y. New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: Effects of targeted disruption of the type 5 adenylyl cyclase gene. J Pharmacol Sci. 2009;109:354-359.
26. Tanaka H, Manita S, Matsuda T, Adachi M, Shigenobu K. Sustained negative inotropism mediated by alpha-adrenoceptors in adult mouse myocardia: developmental conversion from positive response in the neonate. Br J Pharmacol. 1995;114:673-677.
27. Tanaka H, Namekata I, Takeda K, Shimizu Y, Moriwaki R, Hirayama W, et al. Unique excitation -contraction characteristics of mouse myocardium as revealed by SEA0400, a specific inhibitor of Na+-Ca2+ exchanger. Naunyn Schmiedebergs Arch Pharmacol. 2005;371:526-534.
28. Nishimaru K, Tanaka Y, Tanaka H, Shigenobu K. a-Adrenoceptor stimulation-mediated negative inotropism and enhancement of Na+-Ca2+ exchange in mouse ventricle. Am J Physiol. 2001; 280:H132-H141.
29. Sekine T, Kusano H, Nishimaru K, Tanaka Y, Tanaka H, Shigenobu K. Developmental conversion of inotropism by endothelin I and angiotensin II from positive to negative in mice. Eur J Pharmacol. 1999;374:411-415.
30. Nouchi H, Kaeriyama S, Muramatsu A, Sato M, Hirose K, Shimizu N, et al. Muscarinic receptor subtypes mediating positive and negative inotropy in the developing chick ventricle. J Pharmacol Sci. 2007;103:75-82. (Pubitemid 46175597)
31. Nishimaru K, Tanaka Y, Tanaka H, Shigenobu K. Positive and negative inotropic effects of muscarinic receptor stimulation in mouse left atria. Life Sci. 2000;66:607-615.
32. Tanaka H, Nishimaru K, Kobayashi M, Matsuda T, Tanaka Y, Shigenobu K. Acetylcholine-induced positive inotropism mediated by prostaglandin released from endocardial endo- thelium in mouse left atrium. Naunyn Schmiedebergs Arch Pharmacol. 2001;363:577-582.
33. Gover GJ, Sleph PG. Dissociation of cardiodepression from cardioprotection with calcium antagonists: diltiazem protects ischemic rat myocardium with a lower functional cost as compared with verapamil or nifedipine. J Cardiovasc Pharmacol. 1989;14:331-340.
34. Tanaka H, Matsui S, Kawanishi T, Shigenobu K. Use of chloride blockers: a novel approach for cardioprotection against ischemia-reperfusion damage. J Pharmacol Exp Ther. 1996;278:854-861.
35. Namekata I, Nakamura H, Tanaka H, Shigenobu K. Cardio- protection without cardiosuppression by SEA0400, a novel inhibitor of Na+-Ca2+ exchanger, during ischemia-reperfusion injury in guinea-pig myocardium. Life Sci. 2005;77:312-324.
36. Namekata I, Shimada H, Kawanishi T, Tanaka H, Shigenobu K. Reduction by SEA0400 of myocardial ischemia-induced cytoplasmic and mitochondrial Ca2+ overload. Eur J Pharmacol. 2006;533:108-115.
37. Nishida H, Sato T, Ogura T, Nakaya H. New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: Mitochondrial ion channels and cardioprotection. J Pharmacol Sci. 2009;109:341-347.
38. Sanbandam N, Lopaschuk GD, Brownsey RW, Allard MF. Energy metabolism in the hypertrophied heart. Heart Failure Rev. 2002;7:161-173.
39. Agata N, Kato Y, Tanaka H, Shigenobu K. Differential effects of hypoxia on electrical and mechanical activities of isolated ventricular muscles from fetal and adult guinea pigs. Gen Pharmacol. 1994;25:15-18.